Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | KLHL20 | Q9Y2M5 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.31 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290548 | 1.00 | PLK4 (0.43) | PLK4KLHL20HDAC4HDAC1HDAC6 | |
| SCHEMBL10290789 | 0.87 | PLK4 (0.42) | PLK4HDAC4HDAC1HDAC6GHSR | |
| SCHEMBL463836 | 0.87 | PLK4 (0.42) | PLK4HDAC4HDAC1HDAC6GHSR | |
| SCHEMBL415813 | 0.87 | PLK4 (0.49) | PLK4PRSS1PRSS2PRSS3F2 | |
| SCHEMBL414861 | 0.86 | HDAC4 (0.35) | PLK4KLHL20HDAC4HDAC1HDAC6 | |
| SCHEMBL10266892 | 0.86 | HDAC4 (0.35) | PLK4KLHL20HDAC4HDAC1HDAC6 | |
| SCHEMBL10258662 | 0.86 | PLK4 (0.45) | PLK4PRSS1PRSS2PRSS3F2 | |
| SCHEMBL10290482 | 0.86 | PLK4 (0.45) | PLK4PRSS1PRSS2PRSS3F2 | |
| SCHEMBL10258468 | 0.85 | PLK4 (0.43) | PLK4HDAC4HDAC1HDAC6GHSR | |
| SCHEMBL463768 | 0.84 | GHSR (0.40) | PLK4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | PLK4 3151/4885KLHL20 2176/4885HDAC4 1222/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | PLK4 2796/4885KLHL20 2340/4885HDAC4 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.